

Collaborative Working Project Executive Summary

Project title	SMART MDT in Type 2 Diabetes
Organisations involved	Nottingham City GP Alliance Ltd Soar Beyond Ltd Novo Nordisk Ltd
Aims and objectives of the project	<p>The SMART MDT (SMART MDT – Set up and Mobilise, Accelerate, Resources and Tools Multi-disciplinary team) in Type 2 Diabetes (T2DM) project aims to transform the capacity, capability and confidence of the entire primary care workforce to deliver better patient outcomes in T2DM care.</p> <p>This Collaborative Working project will support Nottingham City GP Alliance (NCGPA) to improve their T2DM pathway utilising the whole primary care MDT skillset. This will incorporate utilisation of the innovative, web based Soar Beyond SMART platform with capability mapping function and will produce a robust costed business case to deliver an implementation strategy based on workforce and service development priorities. With an understanding of current service gaps and utilisation of the SMART platform, the intention is to deliver role specific diabetes training and upskilling to better utilise the entire workforce and free up clinical capacity and support the delivery of T2DM healthcare.</p>
Time period (from/to)	The project will commence in January 2022 and run for two years until December 2023. Results of this project will be published on the Novo Nordisk website within 6 months of project completion.
Expected benefits of the project	<p>Benefit to patients:</p> <p>The overall SMART MDT Collaborative Working project has been designed to identify current service gaps and create a model which utilises the most appropriate healthcare professional in the T2DM patient pathway to support the patient living with T2DM to</p>

	<p>receive the appropriate management or intervention at the appropriate time.</p> <p>Patients living with T2DM will benefit by receiving an enhanced primary care service.</p> <p>It is intended that the baseline metrics, such as the number of patients achieving all three treatments targets and having 8 care processes annually, will increase. Patient satisfaction will also be measured.</p>
	<p>Benefit to NHS:</p> <ul style="list-style-type: none"> • Locally defined competencies for each NHS role identified to contribute to patient care in the local T2DM pathway • Capability and competency mapping of existing workforce and highlighting variation and potential skill gaps • Freeing up capacity for traditional clinical roles • Establishment of a workforce recruitment and development plan • Identification of resources and training to address unmet need and upskilling of the identified available workforce to fulfil their potential in delivery of holistic care within the local T2DM pathway <p>Improvement of T2DM patient outcomes as demonstrated by Quality & Outcomes Framework (QoF) and National Diabetes Audit (NDA)</p> <p>Benefit to other Organisations:</p> <ul style="list-style-type: none"> • Soar Beyond - real world use of SMART MDT platform and being able to demonstrate the impact it has had on the NHS and patient outcomes
	<p>Benefit to Novo Nordisk:</p> <ul style="list-style-type: none"> • Enhanced relationship with the NHS through supporting and collaborating with NCGPA to deliver and drive the implementation of a local T2DM pathway to improve patient outcomes

	<ul style="list-style-type: none"> • A heightened understanding of NHS systems, local T2DM services, service reconfiguration & development of relevant roles & responsibilities • Access to the published Collaborative Working project findings & outcomes which can be shared in order to encourage other NHS sites to adopt <p>Novo Nordisk seeks to have no input into any clinical decision making undertaken during this project. However, as a manufacturer of diabetes medications and the medicines optimisation element of this project, there is the potential that Novo Nordisk may benefit from an increase in patients prescribed Novo Nordisk medications already listed on the local formulary and guidelines.</p>
<p>Resource contribution from each organisation involved</p>	<p>Each stakeholder has agreed to contribute an equal financial contribution as part of this agreement:</p> <ul style="list-style-type: none"> • Novo Nordisk will be co funding the platform and providing an NHS Partnerships Manager to support the project management • Nottingham City GP Alliance site will be co funding the platform and providing a senior pharmacist project lead and steering group • Soar Beyond will be subsidising access to the platform for an unlimited number of users and director expertise for the duration of the project